Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Warning issued for Dexcom G6 users as Android 16 update causes compatibility issues
Dexcom has confirmed that the G6 mobile app currently does not work properly with Android 16. If you haven’t yet updated your phone’s software, you are advised not to install the update until Dexcom releases a compatible version of the app.
This warning does not apply to Dexcom G7 or Dexcom One Plus users, and people who haven’t updated to Android 16 are unaffected.
Avoid installing Android 16 if you’re a G6 user.
Check your phone’s settings and turn off automatic software updates to prevent an unintentional upgrade.
If your app is still functioning, it means your phone hasn’t updated yet, keep it that way for now.
If you’ve already installed the update, you might find that the Dexcom G6 app no longer works. This may also affect other devices connected to your CGM system, like the Omnipod 5 insulin pump, which depends on the app for Automated Mode functionality.
Dexcom is collaborating with Google to resolve this, and an app update is expected in the near future.
Use a backup device if you have one, such as a Dexcom G6 receiver or a different phone running an earlier Android version.
Contact your diabetes team – they may be able to supply a Dexcom G7 system temporarily.
If you’re considering rolling back your phone to a previous Android version, speak with your device manufacturer, but be aware this may result in the loss of personal data, including your glucose readings.
If you’re experiencing difficulties managing your insulin due to this issue, it’s crucial to contact your healthcare provider as soon as possible.
We’ll continue to share updates on this situation as soon as we have them. If you have questions or need direct support, you can reach out to Dexcom’s customer care team at 0800 011 6132.
Learn more about insulin pumps, continuous glucose monitors, smart insulin pens and hybrid closed loop systems.
Find out about our work to make T1D treatments available to everyone who needs or wants them.
Find out about our research to find cures for T1D and make everyday life better for those who face it.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition, with the mylife CamAPS FX app now available on iPhones.
We have launched a new 10-year strategy aimed at driving significant advancements in type 1 diabetes (T1D) research, treatment, and care.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
